GALECTIN THERAPEUTICS INC

GALTdata completeness 63%16 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'totalDebt'; no data for concept 'pretaxIncome'

The thesis, from the filings

GALECTIN THERAPEUTICS INC earns about -3418% on equity, but has diluted owners by 9% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own

Figure	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	—	—	—	—	—
Net income	−$30.5M¹	−$38.8M²	−$41.1M³	−$47M⁴	−$30.8M⁴
Operating cash flow	−$24.3M⁵	−$31.1M⁶	−$33M⁷	−$41.8M⁸	−$23.9M⁸
Capital expenditure	—	—	—	—	—
Free cash flow (derived)	—	—	—	—	—
Total debt	—	—	—	—	—
Cash & equivalents	$39.6M⁹	$18.6M¹⁰	$25.7M¹¹	$15.1M¹²	$17.7M¹²
Diluted shares	58.5M	59.4M	60.2M	62.3M	63.9M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$20.02

your share of equity

Profit it earned you last year

−$4.83

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on −$20.02 of net worth that earned you −$4.83 last year.

iii. Is this a good business?

Moat signal · return on equity

-3418% avg · 5y

FY21 -3418%FY22 —FY23 —FY24 —FY25 —

It earned an average -3418% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →

Management signal · capital allocation

+9% shares · 5y

Share count is up 9% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts

10-K · period ending 2021-12-31 · accession 0001140361-23-014658 (NetIncomeLoss)
10-K · period ending 2022-12-31 · accession 0001140361-24-016452 (NetIncomeLoss)
10-K · period ending 2023-12-31 · accession 0001140361-25-011169 (NetIncomeLoss)
10-K · period ending 2024-12-31 · accession 0001140361-26-012155 (NetIncomeLoss)
10-K · period ending 2021-12-31 · accession 0001140361-23-014658 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2022-12-31 · accession 0001140361-24-016452 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2023-12-31 · accession 0001140361-25-011169 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2024-12-31 · accession 0001140361-26-012155 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2021-12-31 · accession 0001140361-23-014658 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2022-12-31 · accession 0001140361-24-016452 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2023-12-31 · accession 0001140361-25-011169 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2024-12-31 · accession 0001140361-26-012155 (CashAndCashEquivalentsAtCarryingValue)